X-Feed Billboard (International)

The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.

GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.

System-State: Number of processed items 45.054 Notifications successully processed since Inception
GlobeNewsWire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US56400P2011
State: 07.01.2025 | 9PM
Wed, 18.12.2024

MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
Mon, 16.12.2024

MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
Wed, 11.12.2024

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
Tue, 05.11.2024

MannKind to Present at 2024 UBS Healthcare Conference
Mon, 04.11.2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
Thu, 31.10.2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease
Mon, 30.09.2024

MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN
Wed, 18.09.2024

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment
Wed, 18.09.2024

コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- 内分泌疾患および希少肺疾患患者を対象とした革新的な吸入治療薬および機器の開発・商業化に取り組んでいる マンカインド・コーポレーション (MannKind Corporation) (NASDAQ: MNKD)は、本日、独立行政法人医薬品医療機器総合機構(PMDA)より、NTM肺疾患の治療を目的としたクロファジミン吸入懸濁液の第3相試験(ICoN-1)の開始許可を取得したと発表した。 この国際的試験は、現在4ヵ国 (米国、日本、韓国、オーストラリア) で保健当局の承認を受けており、5ヵ国目 (台湾) は2024年第4四半期に実施される予定である。

Tue, 27.08.2024

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during fireside chats at three upcoming investor conferences:

Wed, 14.08.2024

KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD
Wed, 07.08.2024

Conference Call to Begin Today at 9:00 a.m. (ET)
Conference Call to Begin Today at 9:00 a.m. (ET)
Sat, 22.06.2024

INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
Wed, 08.05.2024

Conference Call to Begin Today at 5:00 p.m. (ET)
Conference Call to Begin Today at 5:00 p.m. (ET)
Mon, 06.05.2024

MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.